<sent id="26">  At the time of the signing , developing countries that did not recognize patents for pharmaceuticals -LRB- like India and Brazil -RRB- had the option to only do so after a 10 year transition period , a flexibility foreseen in the TRIPS Agreement . </sent> <sent id="27">  Under pressure , Brazil decided to start recognizing patents immediately -LRB- from 1997 on -RRB- , while India chose to do so only in 2005 . </sent> <sent id="28">  That allowed Indian local industry to develop and export not only generic versions of many medicines that are patent protected in most countries , but also to develop new combinations in fixed doses of patented ARVs , which can facilitate adhesion to the treatment due to a reduced number of pills to be ingested . </sent>